Ticker LaunchIPO · ADXN
Addex Therapeutics Ltd.
Addex Therapeutics Ltd. (ADXN) priced its initial public offering on Jan 28, 2020, and listed on Nasdaq. Cooley advised the company.
Addex Therapeutics Ltd. is a clinical-stage pharmaceutical company developing orally available small molecule drugs known as allosteric modulators. These drugs alter the effect of the body's own signaling molecules on a specific receptor or protein, with a primary focus on G-protein coupled receptor targets.
- Status
- IPO
- Ticker
- ADXN
- Exchange
- Nasdaq
- Priced
- Jan 28, 2020
- First filed
- Dec 17, 2019
- Company counsel
- Cooley
- Sector
- Biotech & pharma
- Country / state
- Switzerland
More on this listing for subscribers
- Lock-up period and expiry date
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed Dec 17, 2019
- Latest amendment Jan 23, 2020
- Final prospectus (424B4) Jan 28, 2020
- All filings on EDGAR CIK 1574232
Other Biotech & pharma IPOs in 2020
- PPD, Inc.PPD · Feb 6, 2020 · $1.62B
- Schrodinger, Inc.SDGR · Feb 6, 2020 · $202M
- Arcutis Biotherapeutics, Inc.ARQT · Jan 31, 2020 · $159.4M
- Annovis Bio, Inc.ANVS · Jan 30, 2020 · $12M
- Black Diamond Therapeutics, Inc.BDTX · Jan 30, 2020 · $201.1M
- NovaBridge BiosciencesIMAB · Jan 21, 2020